Shares of Novo Nordisk ended higher on Monday and extended gains in after-hours trading, while "Big Pharma" rival Eli Lilly ...

The decision counters a proposal by the Biden Administration to reimburse beneficiaries for the weight-loss medications.

confirmed that it will not proceed with a Biden administration proposal to expand Medicare coverage for anti-obesity drugs ...

Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries.

A proposal by the Biden administration to cover weight-loss medicines for obesity under Medicare has been axed by the White ...

President Donald Trump has ordered the Department of Health and Human Services to standardize Medicare payments in an effort ...

Novo Nordisk joined the many pharmaceutical companies pushing back on government-negotiated drug pricing in the United States.

The Trump administration has decided not to go forward with a proposal for Medicare and Medicaid to cover high-demand obesity ...

As CMS maintains limits on GLP-1 coverage for weight loss, new efficacy data and shifting prescribing patterns point to sustained high demand across the drug class. Here are four updates: 1. Federal ...

The Trump administration will not permit Medicare to pay for obesity drugs directly ... The decision is a setback for ...

The U.S. announced an increase in Medicare Advantage payment rates for 2026, exceeding expectations and affecting insurer ...

April 14, 2025 Novo Nordisk warns consumers about counterfeit ... in the government's final reimbursement rates for 2026 Medicare Advantage health plans run by private insurers, more than double ...